A CLOSER LOOK AT ELLIPSOID ZONE ATTENUATION Could this structural finding, a newly-approved clinical trial endpoint, help us predict AMD progression? Here’s what we know so far.

Justis P. Ehlers; Charles C. Wykoff

A CLOSER LOOK AT ELLIPSOID ZONE ATTENUATION Could this structural finding, a newly-approved clinical trial endpoint, help us predict AMD progression? Here’s what we know so far.

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

NOVEMBER/ DECEMBER 2024 | RETI NA TODAY.

Original language	English (US)
Pages (from-to)	53-55
Number of pages	3
Journal	Retina Today
Volume	2024-November-December
State	Published - Nov 1 2024

ASJC Scopus subject areas

Ophthalmology

Cite this

@article{084c5f22656446ad8cf939733c044b39,

title = "A CLOSER LOOK AT ELLIPSOID ZONE ATTENUATION Could this structural finding, a newly-approved clinical trial endpoint, help us predict AMD progression? Here{\textquoteright}s what we know so far.",

abstract = "NOVEMBER/ DECEMBER 2024 | RETI NA TODAY.",

author = "Ehlers, {Justis P.} and Wykoff, {Charles C.}",

year = "2024",

month = nov,

day = "1",

language = "English (US)",

volume = "2024-November-December",

pages = "53--55",

journal = "Retina Today",

issn = "1825-0572",

publisher = "Retina Today",

}

TY - JOUR

T1 - A CLOSER LOOK AT ELLIPSOID ZONE ATTENUATION Could this structural finding, a newly-approved clinical trial endpoint, help us predict AMD progression? Here’s what we know so far.

AU - Ehlers, Justis P.

AU - Wykoff, Charles C.

PY - 2024/11/1

Y1 - 2024/11/1

N2 - NOVEMBER/ DECEMBER 2024 | RETI NA TODAY.

AB - NOVEMBER/ DECEMBER 2024 | RETI NA TODAY.

UR - http://www.scopus.com/inward/record.url?scp=85218941208&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85218941208&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:85218941208

SN - 1825-0572

VL - 2024-November-December

SP - 53

EP - 55

JO - Retina Today

JF - Retina Today

ER -

A CLOSER LOOK AT ELLIPSOID ZONE ATTENUATION Could this structural finding, a newly-approved clinical trial endpoint, help us predict AMD progression? Here’s what we know so far.

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this